Health summaries: stay informed and learn faster

The video reviews the benefits and limits of menopause hormone therapy and testosterone treatment when cardiac risk is part of the discussion.

The video frames infertility as a sign of imbalances in toxins, nutrition, the microbiome, and cellular energy before jumping straight to IVF.

Seth Godin explains why resistance points to what matters and how to move with smaller steps, consistent practice, and less attachment to outcomes.

The video explains how deliberate heat exposure can support cardiovascular health, sleep, and mood when it is used consistently and safely.

Light, regular sleep timing, and meal timing affect blood pressure, metabolism, and recovery far more than most people realize.

Pausing, naming what you feel, and dropping self punishment can change your relationship with food. GLP1 may help, but it cannot do the mindset work for you.

Immunotherapy can now reprogram T cells, improve cancer targeting, and move more precise cell based treatments closer to routine care.

Elevated ALT, AST, or GGT after training does not always mean liver damage. Exercise context can completely change how a lab panel should be read.

Matching cleansers, actives, and treatments to each phase of the cycle can reduce breakouts, irritation, oiliness, and sensitivity.

Hormone therapy deserves a clinical reset. Fear driven by the WHI still does not reflect the women most often evaluated during menopause today.

Coronary CTA can reveal soft plaque before calcium scoring or stress tests show disease, making earlier and more targeted treatment possible.

What tests like Galleri actually promise, why stage 1 sensitivity is still low, and when they may deserve a limited supporting role.

Why the gut mucus barrier matters, how intestinal inflammation reaches the brain, and when to prioritize foods rich in L serine.

How irregular sleep may foreshadow neurological decline, why deep sleep matters, and when to think about apnea, alcohol, or CBT I.

What real support peptides have outside GLP 1 drugs, why regulation matters, and how to judge safety, efficacy, and black market risk.